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Desmin-associated myofibrillar myopathy (MFM) has pathologic
similarities to neurodegeneration-associated protein aggregate dis-
eases. Desmin is an abundant muscle-specific intermediate filament,
and disease mutations lead to its aggregation in cells, animals, and
patients. We reasoned that similar to neurodegeneration-associated
proteins, desmin itself may form amyloid. Desmin peptides corre-
sponding to putative amyloidogenic regions formed seeding-
competent amyloid fibrils. Amyloid formation was increased when
disease-associated mutations were made within the peptide, and
this conversion was inhibited by the anti-amyloid compound
epigallocatechin-gallate. Moreover, a purified desmin fragment (aa
117 to 348) containing both amyloidogenic regions formed amyloid
fibrils under physiologic conditions. Desmin fragment-derived amy-
loid coaggregated with full-length desmin and was able to template
its conversion into fibrils in vitro. Desmin amyloids were cytotoxic to
myotubes and disrupted their myofibril organization compared with
desmin monomer or other nondesmin amyloids. Finally, desmin
fragment amyloid persisted when introduced into mouse skeletal
muscle. These data suggest that desmin forms seeding-competent
amyloid that is toxic to myofibers. Moreover, small molecules
known to interfere with amyloid formation and propagation may
have therapeutic potential in MFM.
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Myofibrillar myopathies (MFMs) are a family of geneticallydefined degenerative myopathies that are due to muta-
tions in 2 categories of proteins: Z-disk elements or protein
chaperones (1). Specifically, disease mutations in sarcomeric
structural proteins that reside at the Z-disk such as desmin,
myotilin, filamin C, and Z-band alternatively spliced PDZ-motif
lead to their accumulation and aggregation within myofibers. In
addition, dominantly inherited mutations in protein chaperones
necessary for the proper folding and assembly of these structural
proteins such as αB-crystallin, BAG3, and DNAJB6 lead to
myofibrillar disorganization and accumulation of sarcomeric
proteins such as desmin. MFM patient muscle is unified by
characteristic features that include muscle degeneration, protein
inclusions, congophilic amyloid, and the aggregation of myofi-
brillar proteins such as desmin and myotilin (1, 2).
Desmin is a cardiac- and skeletal muscle-specific type III in-
termediate filament (IF) that is necessary for both myofiber and
myofibril organization (3). Desmin inclusions are present in
pathologic myofibers from patients with MFM (2), and are a
principal component of protein inclusions in other protein ag-
gregate myopathies not due to desmin mutations including ac-
quired myopathies, such as sporadic inclusion body myositis (4).
Dominant or recessively inherited missense mutations or in-
frame deletions in desmin lead to a range of phenotypic syn-
dromes that can include distal myopathy, limb girdle weakness,
congenital weakness, and cardiomyopathy, yet all are unified by
desmin aggregation within the affected tissue (3).
Desmin is a 470-amino acid protein, and more than 70 disease-
associated mutations have been reported that span the entire
protein (3). The formation of desmin IFs occurs via sequentially
ordered steps that include dimer and tetramer formation, unit-
length filament formation, and filament elongation (5). Some
disease mutations affect IF assembly in vitro and in vivo, resulting
in cytosolic inclusions (5, 6). Similarly, disease mutations in the
small heat shock protein αB crystallin affect its ability to facili-
tate desmin filament formation, resulting in desmin aggregation
(7). Desmin aggregates may directly affect myofiber function by
disrupting sarcomere architecture (6). Alternatively, the accu-
mulation of aggregated desmin may affect protein homeostasis,
resulting in chaperone deficiency, proteasome impairment, mi-
tochondrial dysfunction, and up-regulation of autophagy (8–11).
Some studies have demonstrated that desmin aggregates
colocalize to congophilic inclusions or to antibodies detecting pre-
amyloid oligomers (12–14). These studies suggest that desmin may
indeed be amyloidogenic, similar to other aggregate-prone pro-
teins in neurodegeneration such as microtubule-associated protein
tau in Alzheimer’s disease and α-synuclein in Parkinson’s disease.
In normal central nervous system tissue, these proteins are solu-
ble, but in the setting of disease, they aggregate and become in-
soluble (15). In vitro, tau and α-synuclein form amyloid fibers,
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which formation is enhanced when missense mutations associated
with disease are introduced (15).
Self-assembly of amyloidogenic proteins generally follows a
mechanism of nucleated polymerization (16, 17). In this mech-
anism, de novo amyloid formation requires one or more ther-
modynamically unfavorable steps during nucleation. Nucleation
results in sigmoidal assembly kinetics that are characterized by
an initial lag-phase. As a general feature of nucleated polymer-
ization, preformed amyloid structures can template or seed the
conversion of unaggregated and soluble monomeric protein into
the amyloid fold. Amyloid structures can replicate if templated
conversion is coupled with the generation of new seeds; for ex-
ample, by fibril breakage (17, 18). Replication via seeded poly-
merization is thought to underlie the spread of aggregate pathology
within cells and its transmission between cells and organisms in
multiple neurodegenerative diseases, such as Creutzfeldt-Jakob,
Parkinson’s, and Alzheimer’s disease.
While several studies have demonstrated that diseased skeletal
muscle can accumulate aggregate-prone proteins known to form
amyloid in vitro, such as β-amyloid (Aβ) and gelsolin (19), there
is no evidence that a MFM-associated protein is amyloidogenic,
or that it can replicate by a seeding mechanism. The following
study explores the amyloidogenicity of the muscle-specific pro-
tein desmin. We suggest that desmin amyloids are the culprit of
myofiber degeneration and that they may share other amyloid
properties, such as seeding, and may be important mediators of
MFM pathogenesis.
Results
Aggregation of Desmin Fragments into Seeding-Competent Amyloid
Fibrils. We analyzed the amino acid sequence of desmin in silico
for its amyloid propensity, using the prediction algorithm Waltz
(20). Waltz identified 2 highly amyloidogenic regions, from aa 118
to 124 and from aa 280 to 290 (Fig. 1 A, marked by asterisks).
Both regions contained mutations that cause MFM; specifically,
A120D in the first region and A285V in the second region (21,
22). The CamSol algorithm predicted that the A285V mutation
increased hydrophobicity and reduced solubility of the region (23).
To test whether these regions of desmin could indeed form
amyloid, we purified synthetic peptides that spanned either region
(D1, aa112 to 143; D2, aa269 to 290) and that contained either the
wt sequence (D1wt and D2wt) or the disease mutations A120D or
A285V, respectively (D1AD and D2AV). These peptides were
incubated in a wide range of pH conditions to probe their ag-
gregate formation by thioflavin T (ThT) fluorescence (SI Appen-
dix, Fig. S1A). We observed sigmoid kinetics that are typical for
amyloid formation for the D1 peptide (Fig. 1B); the disease mu-
tation A120D accelerated aggregation (Fig. 1B). Similarly, the
D2AV peptide formed ThT-positive aggregates, while the D2wt
peptide remained soluble (Fig. 1C). Atomic force microscopy
(AFM) revealed that all aggregated peptides formed fibrils. D1wt
fibrils had an average height of 4 ± 0.2 nm and a repetitive height
profile that suggests a helical substructure with a repeat length of
32 ± 2 nm (Fig. 1D and SI Appendix, Fig. S1 B–D); D1AD and
D2AV fibrils had similar dimensions to the D1 wt fibrils.
Birefringence of the amyloidophilic dye Congo red (CR) is a
hallmark of amyloid structures. The aggregated peptides bound
CR and displayed both CR fluorescence and apple green bi-
refringence when observed under cross-polarized light (Fig. 1E
and SI Appendix, Fig. S2).
We probed the secondary structure of the desmin peptides by
circular dichroism (CD) to test whether they form β-sheet struc-
tures under our experimental conditions (Fig. 1F). The spectra of
all 4 peptides had minima at 200 nm, typical for unstructured
polypeptides. After 3 d incubation, D1wt, D1AD, and D2AV
peptide spectra showed transitions to a β-sheet structure with
minima at 218 to 220 nm (Fig. 1F), while the D2wt peptide
remained unstructured.
To confirm that amyloid fibers can act as seeds that accelerate
fibril formation, we generated fibril fragments by sonication. The
aggregation of all 3 peptides was strongly accelerated by addition
of these seeds (Fig. 1G). We used the analytical framework de-
veloped by Tuomas Knowles et al. to analyze whether seeding
occurred either via elongation/fragmentation (i.e., a prion mech-
anism) or via secondary nucleation (24). We analyzed the con-
centration dependence of D1wt, D1AD, and D2AV peptide fibril
formation in the AmyloFit algorithm, using models of nucleated
polymerization that included only primary nucleation, primary and
secondary nucleation, primary and secondary nucleation, and
prion replication (SI Appendix, Fig. S3). The data were best de-
scribed by a model in which prion-like replication dominated the
aggregation kinetics; however, seeding by secondary nucleation
may equally contribute to fibril formation. These results all indi-
cate that fragments from the MFM-associated regions of desmin
form seeding-competent, β-sheet rich amyloid fibrils.
Disease Mutations Lower the Critical Concentration of Fibril Formation.
To quantify the role of disease-associated mutations A120D and
A285V in amyloid formation, we analyzed their effect on the
Fig. 1. (A) Schematic diagram of full-length human desmin protein with
amyloidogenic regions D1 and D2. (B and C) ThT aggregation kinetics of D1wt
and D1 A120D peptides (B), and D2 wt and D2 A285V (C), respectively; mean
normalized ThT fluorescence ± SD, n = 3. (D) AFM images of aggregated D1wt,
D1AD, D2wt, and D2AV. D2wt did not form any fibrils. (Scale bar, 350 nm.) (E)
CR birefringence and fluorescence of D1wt peptide aggregates. (Scale bar,
10 μm.) (F) CD spectra of D1wt, D1AD, D2wt, and D2AV peptides incubated for
0 h (red) and 3 d (black), as in B. (G) Aggregation kinetics of D1wt D1AD and
D2AV (0.3 mg/mL), respectively, in the presence of preformed seeds (0.03 mg/mL).
All assays at 37 °C in 20 mM glycine buffer, 100 mM NaCl at pH 2.8.
16836 | www.pnas.org/cgi/doi/10.1073/pnas.1908263116 Kedia et al.
critical concentration in nucleated polymerization (16). The critical
concentration of a polypeptide reflects its amyloidogenicity (24).
We separated soluble from insoluble peptides by ultracentrifuga-
tion (20 min, 100,000 × g) and quantified the peptide in the total
(T) and supernatant (S) fractions by SDS/PAGE and Coomassie
staining (SI Appendix, Fig. S4A). The graphs in SI Appendix, Fig. S4
B–D represent the densitometric analysis of soluble vs. total pep-
tides normalized to the respective highest peptide concentration. As
predicted by the model of nucleated polymerization, the amounts
of soluble peptide remained constant, regardless of the initial
concentration. The relative critical concentrations of the 3 peptides
mirrored their respective aggregation kinetics, with the fastest-
aggregating peptide D1AD having the lowest critical concen-
tration (0.16 ± 0.05 mg/mL, 50 μM), followed by D1 wt (0.3 ±
0.03 mg/mL, 77 μM) and D2AV (0.28 ± 0.06 mg/mL, 121 μM).
These data suggest that the desmin peptide aggregation followed a
nucleated polymerization mechanism, and that the disease-associated
mutations A120D and A285V increased amyloid formation.
Anti-Amyloid Compound EGCG Slows the Aggregation of Desmin
Fragments. Numerous studies have demonstrated that the poly-
phenol epi-gallocatechin gallate (EGCG) is a potent inhibitor of
seeding-competent amyloid fibrils. Desmin peptides D1wt,
D1AD, and D2AV were incubated with EGCG at molar ratios of
0.1 to 5× (EGCG: peptide) to test its effect on desmin fibril
formation. EGCG delayed formation of ThT binding fibrils in a
concentration-dependent manner (Fig. 2 A–C). However, the
compound did not prevent fibril formation, as we previously
observed for Aβ and for α-synuclein (25). To test its effect on
seeding, we collected seeds in the prenucleation phase of desmin
peptides that were incubated with EGCG at equimolar concen-
tration (D1wt, 29 h; D1AD, 11 h; D2AV, 65 h incubation). When
added to fresh monomeric peptide, peptides incubated in the
presence of EGCG displayed much decreased seeding activity
compared with peptide samples that were incubated in the ab-
sence of EGCG (Fig. 2 D and E). From these data, we conclude
that EGCG delayed but did not prevent seed formation at 5×
molar concentration (Fig. 2 G and H).
With Aβ and α-synuclein, EGCG induces the formation of
spherical, SDS-stable aggregates that prevent seeding of amyloid
fibrils (25) However, atomic force microscopy gave no indication
that EGCG induced the formation of spherical aggregates of
desmin fragments. When we probed the formation of SDS-stable
aggregates in the presence of EGCG by SDS/PAGE, we ob-
served no indication of stable aggregates in the presence of SDS
(SI Appendix, Fig. S5). These results indicate that, at our ex-
perimental conditions, the effect of EGCG on desmin more
closely resembled the tau protein rather than Aβ and α-synuclein
aggregation, as the compound delayed, but did not prevent,
nucleation of desmin peptides at low pH.
Desmin Fragment 117 to 348 Forms Seeding-Competent Amyloid
Fibrils under Physiologic Conditions. Short desmin peptides of ei-
ther the D1 or D2 region formed amyloid fibrils only under
acidic conditions. However, longer protein fragments may be
able to form amyloid fibrils under physiological conditions. We
tested this hypothesis by incubating the desmin fragment 117 to
348 that spans both amyloidogenic regions (des117) in 50 mM
Na-phosphate buffer (NaP) at pH 7.4, 100 mM NaCl. Strikingly,
the des117 fragment formed ThT-positive amyloid (Fig. 3 A–C)
that displayed CR fluorescence and birefringence (Fig. 3D).
Electron microscopy revealed that the polypeptide formed 2
types of fibrils with distinct morphologies: narrow straight fibrils
(6.3 ± 0.5 nm diameter), similar to the short desmin peptide D1,
and twisted filaments with 9.0 ± 0.8 nm diameter (Fig. 3A). Similar
morphologies were observed in amyloid-β fibrils (Fig. 3A). Both
types of fibrils had similar average lengths of 150 ± 90 nm and
120 ± 70 nm, respectively. CD spectra showed a transition from a
mostly α-helical structure (26) to an increasingly β-sheet-like
spectrum after 1 and 7 d incubation (Fig. 3E).
However, unlike the short desmin fragments, aggregation ki-
netics of des117 were not dominated by prion-like seeding
in vitro at our experimental concentrations (SI Appendix, Fig. S6
A and B). Rather, des117 aggregation displayed flat concentra-
tion dependence, similar to other folded proteins, such as prion
protein and light chain amyloid formation (27–29). This could
reflect a strong influence of conformational transition on the
kinetics or the presence of alternative aggregation pathways.
Notably, des117 fibrils seeded not only aggregation kinetics of
des117 monomer but also those of full-length desmin (Desmin-
FL) into ThT-positive structures (Fig. 3 B and F). These desmin
fibrils likewise displayed CR birefringence (Fig. 3G) and had
diameters of ∼6 nm (straight fibril) or ∼10 nm (twisted fibril),
typical of amyloid fibrils (Fig. 3 A and B), and CD spectra in-
dicative of β-sheet secondary structure (Fig. 3H). In conclusion,
these data strongly suggest that des117, similar to the shorter
peptide fragments, forms amyloid fibrils that can seed amyloid
formation of full-length desmin protein.
Desmin Amyloid Is Toxic and Persists in Skeletal Muscle. To see
whether desmin amyloids were toxic to skeletal muscle, we dif-
ferentiated primary mouse myoblasts into myotubes and trans-
duced them with monomeric des117, des117 amyloid, or 2
control amyloids, α-synuclein and β-amyloid. Twenty-four hours
after transduction, myotube viability and internal structure were
analyzed. Myotubes treated with des117 amyloid or control
amyloids had a reduction in viability compared with buffer-
treated or des117 monomer control (Fig. 4 A and B). This is
consistent with previous studies demonstrating that amyloidogenic
peptides such as β-amyloid are detrimental to myotubes (30, 31).
It was striking that, although viability was similarly decreased
with different amyloids, des117 amyloid resulted in more
rounded and collapsed myotubes that remained viable but had
lost cytoskeletal integrity (Fig. 4 A and C). This collapse was
specific for the amyloid structure of desmin, since monomeric
des117 did not alter myotube morphology (Fig. 4D). Evaluation
Fig. 2. (A–C) Aggregation of D1wt, D1AD, and D2AV in the presence of
different molar ratios of EGCG (D–F), as in Fig. 1. Peptides incubated in the
presence of EGCG (5:1 molar ratio) were collected as seeds (D1 wt, 24 h;
D1AD, 9 h; D2 AV, 60 h); mean normalized ThT fluorescence ± SD, n = 3.
(D–F) Monomeric peptides were then aggregated without seeds (black), with
fibrillar seeds (10% wt/wt, red) or with seeds formed in presence of EGCG
(green). Seeds formed in the presence of EGCG only weakly accelerated
aggregation kinetics. AFM image of peptide + EGCG seeds for D1wt (G),
D1AD (H), and D2AV (I). (Scale bars, 600 nm.)
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of the internal IF architecture with an antibody to α-actinin
demonstrated striated sarcomeric structures in control-treated
myotubes that were lost in the collapsed des117 amyloid-treated
myotubes, which had a more diffuse and homogenous α-actinin
distribution (Fig. 4E).
To explore the behavior of desmin amyloids on skeletal muscle
in vivo, we electroporated mouse tibialis anterior skeletal muscle
with similar amounts of fluorescently labeled monomeric des117,
des117 amyloid, or, as a control amyloid, α-synuclein, along with
an expression vector containing GFP-desmin. After 7 d of ex-
pression and recovery from the electroporation, we isolated the
tibialis anterior and sectioned the muscle for confocal fluores-
cence microscopy (Fig. 4F). While desmin-GFP was expressed
similarly in transduced fibers, only des117 amyloid remained
within the fiber compared with α-synuclein or monomeric des117.
Des117 amyloid did not colocalize with transduced GFP-desmin,
suggesting that they did not incorporate into desmin IFs.
Fig. 3. (A) Negative stain transmission electron microscopy images of Desmin
117, D1 wt, and Aβ 1 to 42 fibrils. (Scale bars, 200 nm.) Desmin formed narrow,
straight fibrils and twisted fibrils with more than one filament. Both mor-
phologies are also observed in Aβ 42. Fibril diameters were measured using
ImageJ; mean ± SD, n = 20. (B) AFM images of full-length desmin fibrils in the
absence and presence of 10% fibrillar des117 seeds. (Middle) Highlighted area
containing straight fibrils of ∼6 nm height. (Scale bar, Top: 400 nm; Bottom:
100 nm.) (C) Aggregation of desmin 117 to 348 peptide (des117, 0.55 mg/mL)
10% fibrillar des117 seeds; mean normalized ThT fluorescence ± SD, n = 3. (D)
Des117 aggregate CR fluorescence and birefringence. (Scale bar, 25 μm.) (E) CD
spectra of des117 at 0 h and after 1 d of aggregation. (F) Aggregation kinetics
of full-length desmin with 10% fibrillar des117 seeds. (G) Desmin aggregate CR
fluorescence and birefringence. (Scale bar, 25 μm.) (H) CD spectra of full-length
desmin after 0 h and 1 and 7 d incubation. All reactions (A–H) at 37 °C in
50 mM NaP buffer at pH 7.4, 100 mM NaCl. **P < 0.001; ***P < 0.0001.
Fig. 4. (A) Primary mouse myotubes treated with buffer, des117 monomer,
des117 amyloid, or control amyloids (Aβ or α-synuclein) immunostained with
an anti-desmin antibody. Arrows denote collapsed myofibers. (B) MTT via-
bility assay of cells in A as a percentage of untreated control cells (dashed
line); mean ± SD, n = 12. (C–D) Quantitation of the percentage of collapsed
fiber in primary mouse myotubes treated with buffer, des117 monomer,
des117 amyloid, Aβ 42 or α-synuclein (n = 10; >1,000 myotubes/condition).
(E) Primary myotubes treated with buffer or des117 amyloid and stained
with anti α-actinin antibody. Collapsed fibers have diffuse α-actinin staining,
as opposed to elongated fibers with sarcomeric structure. (F) Confocal im-
ages of cryosections of tibialis anterior muscle electroporated with GFP-
desmin and fluorescently labeled α-synuclein fibrils, des117 amyloid or
des117 monomer. (G) Confocal images of cryosections of tibialis anterior
muscle electroporated with fluorescently labeled des117 amyloid then
stained with an antibody recognizing the C terminus or an epitope within
the desmin fragment (pan-desmin). Blue is DAPI-stained nuclei. *P < 0.01;
**P < 0.001; ***P < 0.0001; n.s., not significant. (Scale bars: A, E, Left, F, and
G, 50 μm; E, Right, 10 μm.)
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IF disruption or incorporation was also not apparent when we
transiently transfected an expression vector containing an N-terminal
GFP tagged desmin and transduced fluorescently labeled des117,
aggregated α-synuclein, aggregated des117, or aggregated full-
length desmin protein into SW13 cells (SI Appendix, Fig. S7A).
SW13 cells are an adrenal carcinoma cell line that lacks type III
IFs such as vimentin and desmin, allowing one to evaluate newly
synthesized IF formation. In addition, desmin 117 amyloid did
not coaggregate with GFP-labeled full-length desmin when using
MFM disease-associated mutations GFP-desmin-D399Y or
GFP-desmin-R350P that form sarcoplasmic aggregates when
electroporated into mouse tibialis anterior in vivo (SI Appendix,
Fig. S7B).
To further evaluate the localization of transduced des117
amyloid, we electroporated only fluorescently tagged des117
amyloid into muscle and performed fluorescent immunohisto-
chemistry with 2 desmin antibodies. One antibody directed to the
C terminus of desmin recognizes only endogenous desmin, since
the exogenous desmin amyloid is truncated at amino acid 348.
The second antibody recognizes both the des117 fragment and
endogenous desmin. Similar to coexpression of exogenous
desmin-GFP, des117 amyloid persisted in the sarcoplasm of the
electroporated skeletal muscle fiber, but there was no apparent
colocalization with endogenous FL-desmin within the fiber
containing des117 amyloid seeds, confirming the previous results
with GFP-desmin coexpression (Fig. 4G).
Discussion
Pathogenic mutations in desmin lead to muscle diseases with
prominent protein inclusions within affected myofibers (3).
Mutations in several other muscle specific proteins also lead to
myopathies with protein inclusions or MFMs (1). In desmin-
associated MFM, a dominantly inherited missense mutation
causes it to misassemble and aggregate. Inclusions in MFMs often
stain with CR and can demonstrate birefringence, which is one of
the hallmarks of amyloid structures (19). The current study
demonstrates that desmin itself has amyloidogenic properties.
Desmin amyloids can propagate the aggregation of naive, unag-
gregated, monomeric desmin. We suggest that amyloidogenic
conversion of desmin may underlie the pathogenesis of MFMs.
Desmin is the primary IF in skeletal and cardiac muscle.
Notably, all MFMs, regardless of genetic etiology, contain desmin
inclusions, suggesting that desmin aggregates unify MFM path-
ogenesis (19). We reasoned that desmin may actually be an
amyloidogenic protein with properties similar to other proteins
in neurodegenerative disorders. Several algorithms have been
developed to predict amyloidogenicity based on hydrophobicity,
amino acid composition, and sequence (20, 23). Indeed,
Waltz identified 2 amyloidogenic regions that contained amino
acids mutated in MFM. Peptides corresponding to these regions
made amyloid in vitro that was 8 to 10 nm in height, bound ThT,
displayed CR birefringence, had predominant β-sheet structures,
and were competent to accelerate fibril formation through
seeding. Moreover, a larger desmin fragment 117 to 348 that
spanned both regions aggregated into fibrils with similar prop-
erties under physiological conditions. These fibrils coaggregated
with full-length desmin protein and could seed the formation of
fibrils with amyloid-like properties in vitro. CR fluorescent-
positive amyloid structures are a feature found in some muscle
biopsies from patients with MFM. In some cases, congophilic
inclusions seem to colocalize with desmin aggregates on serial
sectioned muscle biopsies (14). However, whether desmin is the
congophilic species is not known. Our results suggest that desmin
and its fragments can form congophilic aggregates that persist in
muscle fibers. The mechanism by which desmin seeds persist,
while unaggregated desmin does not, is unclear. It is conceivable
that once aggregated, desmin is not cleared by normal pro-
teolytic pathways such as the proteasome or autophagy, or that
protein chaperones necessary for this process fail to recognize
desmin amyloids leading to their selective persistence (3).
Several studies have expressed an amyloidogenic protein in
skeletal or cardiac muscle to model a protein aggregate myop-
athy. These include expression of an expanded poly-glutamine
containing protein, amyloid precursor protein, and gelsolin (32–
34). Interestingly, all these models develop aged onset muscle
dysfunction with fiber degeneration, amyloid inclusions, and in
some cases, secondary aggregation of other proteins suggesting
that amyloidogenic proteins can lead to disease (33, 34). The
accumulation of proteins known to aggregate and form amyloid
in neurodegenerative disorders are also present in tissue from
patients with MFM and include TDP-43 and β-amyloid (19, 35).
However, mutations in these proteins have not been found in
patients with MFM or other protein aggregate myopathies,
suggesting that their accumulation is secondary (36). Proteomic
studies have consistently identified desmin as one of the most
abundant proteins found in protein aggregates in MFM and
other aggregate myopathies not associated with desmin muta-
tions (4, 37, 38). In addition, posttranslational modification of
desmin into phosphorylated fragments has been suggested to
enhance its amyloidogenicity in vivo (12).
The mechanism of nucleated polymerization allows for mul-
tiple competing pathways of nucleation and replication (17, 24).
Our data suggest that the self-assembly of unfolded desmin
fragments spanning the amyloidogenic regions of the protein is
dominated by seed elongation and fragmentation, which is typ-
ical for prion replication. While accelerated by seeding, the
amyloid formation of the natively folded desmin 117 to 348 does
not show concentration dependence. This suggests its aggrega-
tion rate may be limited by a conformational change, as has been
observed for other folded amyloidogenic proteins, such as anti-
body light chain and the prion protein (27–29). Star-shaped fibril
clusters formed by full-length desmin, similar to those observed
in huntingtin aggregation, suggest a role of nucleated branching
in fibril formation.
Amyloid structures are believed to persist and replicate in
skeletal muscle. Most notably, the form of the prion protein
(PrP) found in infectious prions, PrPSc, likely incubates in the
skeletal muscle of cattle, where it can then transmit to uninfected
animals resulting in bovine spongiform encephalopathy (39). It
has also been shown that α-synuclein aggregates when injected
into skeletal muscle induce central nervous system α-synuclein
pathology and motor impairment (40). Interestingly, there was
no α-synuclein pathology in the injected skeletal muscle (40).
This is similar to our data demonstrating that only desmin amyloid
seeds persisted in skeletal muscle, whereas α-synuclein seeds were
labile. It is conceivable that there is tissue specific tropism for
muscle-derived versus central nervous system-derived amyloid
species. Our data, along with others, support that skeletal muscle
is a suitable reservoir for the persistence and replication of amy-
loid structures by prion or prion-like mechanisms.
One feature of prion diseases is the pathogenic spread of ag-
gregate pathology from cell to cell via templated aggregate
conversion. Whether this process occurs in skeletal muscle is not
known. Notably, this mechanism is distinct from the expression
of a destabilized desmin variant that aggregates upon in-
termediate filament assembly. Our studies demonstrated tem-
plated conversion of full-length desmin by desmin amyloid, but
this was not recapitulated in cells or skeletal muscle. Indeed,
desmin amyloid did not incorporate into native desmin filaments
and desmin aggregates, nor did they disrupt IF formation under
the conditions tested. Exogenous desmin amyloid, similar to
other amyloids, was toxic to myotubes in culture, suggesting that
amyloidogenic species in themselves can lead to myofiber dys-
function. Unique to treatment with exogenous desmin amyloid,
myotubes collapsed and lost sarcomere integrity. In addition,
desmin amyloid persisted in mouse skeletal muscle compared
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with desmin monomers or α-synuclein aggregates. This discrep-
ancy between in vitro and in vivo studies is intriguing and may
relate to the unconstrained biophysical properties of proteins in
solution versus in cells that have a complete proteostatic network
of chaperones and clearance mechanisms. Alternatively, the
substrate of desmin amyloid propagation in vivo may be a pro-
teolytic fragment of desmin, which would not have been detected
by GFP or antibody staining. A similar mechanism is observed in
the seeded propagation of the huntingtin protein, light chain
amyloid, and PrPSc, all of which preferentially or exclusively in-
corporate proteolytically truncated forms of the protein (18, 41).
The spread of aggregate pathology could conceivably propa-
gate within the myofiber corrupting the Z-disk of adjacent or
nearby sarcomeres. Alternatively, a toxic aggregate may escape a
diseased myofiber and be actively taken by an adjacent fiber.
This mechanism may explain the large regions of aggregate pa-
thology and myofiber atrophy in MFMs (19).
The aggregation of proteins into amyloid structures and their
subsequent spread via prion replication could have profound im-
plications for therapeutic strategies in myodegenerative diseases.
Therapeutic intervention that inhibits amyloid formation and in-
activates seeds could halt replication. While no such clinical ther-
apy exists today in neurodegenerative diseases, model compounds,
such as EGCG, have been highly effective in inactivating amyloid
seeds and inhibiting replication in vitro by sequestering them into
seeding-inactive aggregates (25, 28). However, its mechanism de-
pends on the relative stabilities of aggregation intermediates, fibrils,
and EGCG-induced aggregates (25, 28). Future studies in mouse
models of desmin aggregation and propagation will have to de-
termine whether EGCG is a promising model compound for
desminopathy in vivo.
Experimental Methods
ThT Aggregation Assay. Aggregation of synthetic desmin peptides (D1 wt, D1
AD, D2 wt, D2 AV, Watson Bio; 0.33 mg/mL) was monitored by ThT fluo-
rescence in 20 mM glycine buffer with 100 mM NaCl in a fluorescent plate
reader, as described previously (25, 28). For aggregation of full-length des-
min and des117 aggregation (CloudClone), 50 mM NaP buffer at pH 7.4,
100 mM NaCl was used.
Primary Myotube Assays. Primary mouse myoblasts were differentiated into
myotubes and then transducedwith 0.05 μg/μL unaggregated des117, des117
amyloid, α-synuclein fibrils or β-amyloid fibers in fusion medium using
Lipofectamine 2000 for 24 h and assessed for toxicity and morphology, as de-
scribed in the SI Appendix, which also contains additional SI Appendix,
Experimental Methods.
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